Drug Ther Bull. 2008 Apr;46(4):25-9. doi: 10.1136/dtb.2008.03.0008.
The glitazones and their combination products are licensed for type 2 diabetes mellitus and now account for over 50% of NHS expenditure on oral hypoglycaemic drugs. In 2001, for pioglitazone and rosiglitazone (the two glitazones licensed in the UK), we concluded that evidence (from short-term studies) supported their use in combination with metformin or a sulphonylurea in patients unsuited to one or other of these drugs, but not more practical glitazone use, such as monotherapy or as part of triple therapy. We also said that their long-term effects were not yet clear. Since then, both drugs have also been licensed for monotherapy, as part of triple therapy that includes metformin and a sulphonylurea and, for pioglitazone, use with insulin. Here we reassess glitazones in light of published efficacy data and safety concerns raised in recent years.
格列酮类药物及其复方制剂被批准用于治疗2型糖尿病，目前占英国国家医疗服务体系（NHS）口服降糖药支出的50%以上。2001年，对于吡格列酮和罗格列酮（在英国获批的两种格列酮类药物），我们得出结论：（来自短期研究的）证据支持在不适合单独使用二甲双胍或磺脲类药物的患者中，将它们与二甲双胍或磺脲类药物联合使用，但不支持更实际的格列酮类药物使用方式，如单药治疗或作为三联疗法的一部分。我们还表示，它们的长期影响尚不清楚。从那时起，这两种药物也被批准用于单药治疗、作为包括二甲双胍和磺脲类药物的三联疗法的一部分，以及吡格列酮与胰岛素联合使用。在此，我们根据近年来公布的疗效数据和安全问题对格列酮类药物进行重新评估。
